Post-transplant lymphoproliferative disorder
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Post-transplant lymphoproliferative disorder Classification and external resources | |
| ICD-O: | M9970/1 |
|---|---|
| DiseasesDB | 34154 |
| eMedicine | ped/2851 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Post-transplant lymphoproliferative disorder (PTLD) is the name given to a group of B cell lymphomas occurring in immunosuppressed patients following organ transplant.
Incidence/prevalence
It is an uncommon condition occurring in 0.2% of patients within one year of transplant, with an annual incidence of 0.04% thereafter. The risk of developing the disease is higher in children and recipients of heart transplants.
Causes
The disease is an uncontrolled proliferation of B cell lymphocytes following infection with Epstein-Barr virus. Production of an interleukin-10, an endogenous anti-T cell cytokine, has also been implicated.
In immunocompetent patients, Epstein-Barr virus causes infectious mononucleosis, characterised by a proliferation of B-lymphocytes which is controlled by Suppressor T cells.
However, calcineurin inhibitors (tacrolimus and cyclosporine) used as immunosuppressants in organ transplantation inhibit T cell function, and can prevent the control of the B cell proliferation.
Depletion of T cells by use of anti-T cell antibodies in the prevention or treatment of transplant rejection further increases the risk of developing post-transplant lymphoproliferative disorder. Such antibodies include ATG, ALG and OKT3.
Polyclonal PTLD may form tumor masses and present with symptoms due to a mass effect, e.g. symptoms of bowel obstruction. Monoclonal forms of PTLD tend to form a disseminated malignant lymphoma.
Treatment
PTLD may spontaneously regress on reduction or cessation of immunosuppressant medication, and can also be treated with addition of anti-viral therapy. In some cases it will progress to non-Hodgkin's lymphoma and may be fatal.
Organ transplantation | |
|---|---|
| Types | Allograft · Alloplant · Allotransplantation · Autotransplantation · Xenotransplantation |
| Organs and tissues | Bone · Bone marrow · Corneal · Face · Hand · Heart · Heart-lung · Kidney · Liver · Lung · Pancreas · Penis · Skin · Spleen · Uterus |
| Related topics | Biomedical tissue · Cellular memory · Edmonton protocol · Eye bank · Graft-versus-host disease · Immunosuppressive drugs · Islet cell transplantation · Implants · Living donor liver transplantation · Lung allocation score · Machine perfusion · Medical grafting · Non-heart beating donation · Organ donation · Post-transplant lymphoproliferative disorder · Repugnant market · Total body irradiation · Transplant rejection |
| Organizations | Halachic Organ Donor Society · Human Tissue Authority · National Marrow Donor Program · United Network for Organ Sharing |
| People | Christiaan Barnard · Michael Woodruff · Alexis Carrel · Norman Shumway · Jean-Michel Dubernard · List of notable organ transplant donors and recipients |
WikiDoc Research Resources for Post-transplant lymphoproliferative disorder (Click show to right to view) | |
|---|---|
| Articles on Post-transplant lymphoproliferative disorder | Most recent articles on Post-transplant lymphoproliferative disorder • Most cited articles on Post-transplant lymphoproliferative disorder • Review articles on Post-transplant lymphoproliferative disorder • Articles on Post-transplant lymphoproliferative disorder in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on Post-transplant lymphoproliferative disorder | Powerpoint slides on Post-transplant lymphoproliferative disorder • Images of Post-transplant lymphoproliferative disorder • Photos of Post-transplant lymphoproliferative disorder • Podcasts & MP3s on Post-transplant lymphoproliferative disorder • Videos on Post-transplant lymphoproliferative disorder |
| Evidence Based Medicine Regarding Post-transplant lymphoproliferative disorder | Cochrane Collaboration on Post-transplant lymphoproliferative disorder • Bandolier on Post-transplant lymphoproliferative disorder • TRIP on Post-transplant lymphoproliferative disorder |
| Cost Effectiveness of Post-transplant lymphoproliferative disorder | Cost Effectiveness of Post-transplant lymphoproliferative disorder |
| Clinical Trials Involving Post-transplant lymphoproliferative disorder | Ongoing Trials on Post-transplant lymphoproliferative disorder at Clinical Trials.gov • Trial results on Post-transplant lymphoproliferative disorder • Clinical Trials on Post-transplant lymphoproliferative disorder at Google |
| Guidelines / Policies / Government Resources (FDA/CDC) Regarding Post-transplant lymphoproliferative disorder | US National Guidelines Clearinghouse on Post-transplant lymphoproliferative disorder • NICE Guidance on Post-transplant lymphoproliferative disorder • NHS PRODIGY Guidance • FDA on Post-transplant lymphoproliferative disorder • CDC on Post-transplant lymphoproliferative disorder |
| Textbook Information on Post-transplant lymphoproliferative disorder | Books and Textbook Information on Post-transplant lymphoproliferative disorder |
| Pharmacology Resources on Post-transplant lymphoproliferative disorder | Dosing of Post-transplant lymphoproliferative disorder • Drug interactions with Post-transplant lymphoproliferative disorder • Side effects of Post-transplant lymphoproliferative disorder • Allergic reactions to Post-transplant lymphoproliferative disorder • Overdose information on Post-transplant lymphoproliferative disorder • Carcinogenicity information on Post-transplant lymphoproliferative disorder • Post-transplant lymphoproliferative disorder in pregnancy • Pharmacokinetics of Post-transplant lymphoproliferative disorder • |
| Genetics, Pharmacogenomics, and Proteinomics of Post-transplant lymphoproliferative disorder | Genetics of Post-transplant lymphoproliferative disorder • Pharmacogenomics of Post-transplant lymphoproliferative disorder • Proteomics of Post-transplant lymphoproliferative disorder |
| Newstories on Post-transplant lymphoproliferative disorder | Post-transplant lymphoproliferative disorder in the news • Be alerted to news on Post-transplant lymphoproliferative disorder • News trends on Post-transplant lymphoproliferative disorder |
| Commentary on Post-transplant lymphoproliferative disorder | Blogs on Post-transplant lymphoproliferative disorder |
| Patient Resources on Post-transplant lymphoproliferative disorder | Patient resources on Post-transplant lymphoproliferative disorder • Discussion groups on Post-transplant lymphoproliferative disorder • Patient Handouts on Post-transplant lymphoproliferative disorder • Directions to Hospitals Treating Post-transplant lymphoproliferative disorder • Risk calculators and risk factors for Post-transplant lymphoproliferative disorder |
| Healthcare Provider Resources on Post-transplant lymphoproliferative disorder | Symptoms of Post-transplant lymphoproliferative disorder • Causes & Risk Factors for Post-transplant lymphoproliferative disorder • Diagnostic studies for Post-transplant lymphoproliferative disorder • Treatment of Post-transplant lymphoproliferative disorder |
| Continuing Medical Education (CME) Programs on Post-transplant lymphoproliferative disorder | CME Programs on Post-transplant lymphoproliferative disorder |
| International Resources on Post-transplant lymphoproliferative disorder | Post-transplant lymphoproliferative disorder en Espanol • Post-transplant lymphoproliferative disorder en Francais |
| Business Resources on Post-transplant lymphoproliferative disorder | Post-transplant lymphoproliferative disorder in the Marketplace • Patents on Post-transplant lymphoproliferative disorder |
| Informatics Resources on Post-transplant lymphoproliferative disorder | List of terms related to Post-transplant lymphoproliferative disorder |
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
